Literature DB >> 1676689

Immunopathogenesis of HIV infection.

Z F Rosenberg1, A S Fauci.   

Abstract

The ultimate consequence of infection with HIV is profound immunosuppression that is the result of both quantitative and qualitative abnormalities of the helper/inducer subset of T lymphocytes. The initial pathogenic event in HIV infection is binding of the envelope glycoprotein of HIV to the CD4 receptor molecule present on the surface of CD4+ T lymphocytes and monocyte/macrophages. In vivo the reservoir for HIV infection in the peripheral blood is the CD4+ T cell, whereas in other tissues the monocyte/macrophage may play a substantial role. As disease progresses in HIV-infected individuals, the viral burden in the peripheral blood CD4+ T cells increases. An understanding of the mechanisms involved in the transition from an initially low viral burden during the asymptomatic phase of HIV infection to the higher levels of virus expression detected in late stage disease is being investigated intensively. A number of potential agents that may influence regulation of HIV expression have been identified including mitogens, antigens, heterologous viruses, cytokines, and physical factors. The pathogenic mechanisms of HIV-induced neurologic abnormalities and the potential role of HIV in a number of other clinical manifestations of HIV infection are also discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676689     DOI: 10.1096/fasebj.5.10.1676689

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  42 in total

1.  Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection.

Authors:  R S Veazey; K G Mansfield; I C Tham; A C Carville; D E Shvetz; A E Forand; A A Lackner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.

Authors:  J P Lai; W Z Ho; G X Zhan; Y Yi; R G Collman; S D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells.

Authors:  J P Taylor; C Cupp; A Diaz; M Chowdhury; K Khalili; S A Jimenez; S Amini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

Review 4.  Molecular anatomy of viral persistence.

Authors:  M B Oldstone
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

Review 5.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Authors:  Kayvon Modjarrad; Eric Chamot; Sten H Vermund
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

Review 6.  Role of oxidants in microbial pathophysiology.

Authors:  R A Miller; B E Britigan
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

7.  The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication.

Authors:  L Duan; I Ozaki; J W Oakes; J P Taylor; K Khalili; R J Pomerantz
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis.

Authors:  S Sabbaj; M F Para; R J Fass; P W Adams; C G Orosz; C C Whitacre
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

9.  Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals.

Authors:  M C Hannibal; D M Markovitz; N Clark; G J Nabel
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Chronic human immunodeficiency virus type 1 infection stimulates distinct NF-kappa B/rel DNA binding activities in myelomonoblastic cells.

Authors:  A Roulston; P Beauparlant; N Rice; J Hiscott
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.